OncRef
Skip to newsletter content
|
LymphomaJuly 2026
0:00 / 2:07
Lymphoma — Monthly Compass
Jul 01–31, 2026 • Priority Updates • 3–5 minute read
 
A curated, practice-minded digest of what moved in lymphoma this month — regulatory signals, clinical development, and the most practice-relevant publications.
Built for oncologists OncRef Curated Oncology Intelligence Layer
lymphoma updates
Key Highlights
Key Highlights
  • Key Clinical Development Updates
    • FDA granted both RMAT and Fast Track designations to Allogene’s allogeneic CD19 CAR T cemacabtagene ansegedleucel as first‑line consolidation for MRD‑positive large B‑cell lymphoma, citing supportive ALPHA3 futility‑analysis findings and enabling enhanced FDA engagement with potential expedited review.
    • Genmab and AbbVie reported that overall survival—the sole U.S. primary endpoint—in the Phase 3 EPCORE DLBCL‑1 trial of epcoritamab in relapsed/refractory DLBCL was not met, while the therapy maintains FDA accelerated approval in R/R DLBCL and high‑grade B‑cell lymphoma after at least two prior lines with additional results to be submitted for publication.
  • Important Clinical Trial Publications
    • In the Phase 2 SIDNEY study for indolent NHL, EO2463‑induced CD8 T‑cell expansion correlated with progression‑free survival on monotherapy and with complete response on EO2463 plus lenalidomide/rituximab, with tolerability described as favorable.
  • Key Conference Updates
    • The July 20–24, 2026 Pan Pacific Lymphoma Conference spotlighted early‑intervention immunotherapy in watch‑and‑wait indolent NHL and featured practical debates on transplant‑centric care.
  • Emerging Themes & Macro-Trends
    • Antibody modalities (radiolabeled antibodies, ADCs, bispecifics) and CAR T are converging as coequal pillars across B‑cell lymphomas, expanding sequencing and combination frameworks and driving earlier‑line integration strategies.
    • In vivo CAR T is entering the clinic for B‑cell malignancies with FDA IND clearance for Umoja’s CD22‑directed UB‑VV400 and first dosing expected in Q3 2026, signaling modality expansion beyond ex vivo manufacturing.
FDA Approvals/Withdrawals
FDA Approvals/Withdrawals
  • On July 14, 2026, the FDA granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients with locally advanced or metastatic RET fusion-positive solid tumors, including those relevant to hematological malignancies, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. This approval was based on efficacy data from the LIBRETTO-001 and LIBRETTO-121 trials, demonstrating overall response rates and duration of response in various tumor types. The prescribing information includes warnings for hepatotoxicity, interstitial lung disease/pneumonitis, hypertension, and other adverse events.¹ (read more)
  • On July 9, 2026, the FDA approved isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis U.S. LLC) for subcutaneous injection for multiple myeloma indications. This approval covers its use in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, and bortezomib, lenalidomide and dexamethasone, for various patient populations with multiple myeloma. Efficacy was evaluated in the IRAKLIA, IZALCO, and IsaSocut trials, showing favorable overall response rates.² (read more)
Clinical Development Regulatory Updates
Clinical Development Regulatory Updates
  • Allogene Therapeutics reported that FDA granted both RMAT and Fast Track designations to its allogeneic CD19 CAR T therapy cemacabtagene ansegedleucel (cema-cel) as first-line consolidation for adults with large B-cell lymphoma who are MRD-positive after initial therapy, enabling enhanced FDA engagement and potential expedited review pathways. The company highlighted ALPHA3 futility-analysis findings as supportive of these designations. ¹ (read more)
  • Umoja Biopharma announced FDA clearance of its IND for UB-VV400, a CD22-directed in vivo CAR T therapy, with first dosing expected in Q3 2026; the Phase 1/2 VIBRANT-1 trial will enroll adults with relapsed/refractory B‑cell malignancies, including lymphomas. The IND clearance expands Umoja’s in vivo CAR T pipeline targeting B‑cell cancers. ² (read more)
  • Genmab and AbbVie clarified that overall survival was the sole U.S. primary endpoint in the Phase 3 EPCORE DLBCL-1 trial of epcoritamab in relapsed/refractory DLBCL and that this endpoint was not met, while reiterating that epcoritamab currently holds FDA accelerated approval in R/R DLBCL and high‑grade B‑cell lymphoma after two or more prior lines. The companies said additional study results will be submitted for publication. ³ (read more)
  • Curis announced updated data for emavusertib and noted ongoing regulatory interactions for its registrational PCNSL program, stating that prior FDA and EMA meetings indicated the ongoing study could support an application for accelerated approval in relapsed/refractory primary CNS lymphoma. The update also outlined plans for continued engagement as the company advances its lymphoma and CLL studies. ⁴ (read more)
Conference
Major Conference Updates
Conference Information
  • Pan Pacific Lymphoma Conference (PPLC), Fairmont Orchid, Kohala Coast (Big Island), Hawaii; July 20–24, 2026. Strong clinical momentum with early-intervention immunotherapy signals and practical debates on transplant-centric care. (read more)
  • AACR Special Conference: Advances in Malignant Lymphoma: From Discovery to Clinical Impact, Philadelphia, PA; June 24–27, 2026 (covered July 9). Antibody-based modalities (radiolabeled mAbs, ADCs, bispecifics) and CAR T highlighted as converging pillars. (read more)
  • Theme 1: Early Interception in Watch-and-Wait iNHL
    • Significance: First credible move to treat low–tumor-burden iNHL proactively, aiming to extend PFS without compromising quality of life; potential to redefine “watch and wait.” (read more)
    • Mechanism insights / clinical impact: EO2463 (OncoMimics) uses four synthetic microbial-derived peptides mimicking CD20/CD22/CD37/CD268 plus UCP2 to expand memory CD8 T cells; higher CD8 expansion correlated with longer PFS on EO2463 monotherapy and with CR on EO2463+lenalidomide/rituximab (R²). Tolerability described as favorable. (read more)
    • Patient populations affected: Indolent NHL (follicular lymphoma, marginal zone lymphoma) in watch-and-wait and relapsed/refractory settings; older/frail patients prioritized. (read more)
  • Theme 2: Modality Diversification with Antibody Platforms and CAR T
    • Significance: Multi-modality antibody era (radiotherapeutics, ADCs, bispecifics) alongside CAR T is broadening options and pressuring earlier-line integration strategies. (read more)
    • Mechanism insights / clinical impact: Radiolabeled antibodies deliver targeted radiation; ADCs add cytotoxic payloads; bispecifics redirect T cells; CAR T offers deep, durable remissions—collectively enabling sequencing/combination frameworks across B‑cell lymphomas. (read more)
    • Patient populations affected: Broad B‑cell lymphoma spectrum across lines of therapy, with growing consideration of frontline deployment in select groups. (read more)
  • Theme 3: Immune Biomarkers to Guide Therapy
    • Significance: Pharmacodynamic biomarkers are moving from correlative to decision-informing; potential for trial enrichment and adaptive designs. (read more)
    • Mechanism insights / clinical impact: In SIDNEY, magnitude of EO2463‑induced CD8 expansion associated with PFS (monotherapy) and CR (EO2463+R²), supporting CD8 expansion as a predictive biomarker and accelerating registrational planning. (read more)
    • Patient populations affected: iNHL cohorts spanning watch‑and‑wait, first‑line low–tumor‑burden, and relapsed/refractory disease. (read more)
  • Theme 4: EBV‑Driven T/NK Lymphomas—Transplant‑Centric Urgency
    • Significance: Persistent gap for targeted drugs; rapid referral for allogeneic HCT remains essential and time‑sensitive. (read more)
    • Mechanism insights / clinical impact: Chronic active EBV in T/NK cells is highly aggressive; allo‑HCT is the only curative path, making early recognition and center transfer critical. (read more)
    • Patient populations affected: Rare EBV‑positive T/NK lymphomas; emphasis on centers with transplant expertise. (read more)
  • Significance
    • Expected clinical or translational readouts: EO2463 advancing toward registrational development in iNHL with biomarker integration; additional antibody‑modality data expected at fall congresses (e.g., ESMO/ASH). (read more)
    • Regulatory or policy implications: EO2463 holds FDA Orphan Drug Designation in FL, potentially expediting pathways. (read more)
    • Potential shifts in standard of care: If interception improves PFS with low toxicity, a new early‑treatment paradigm in iNHL may emerge; antibody platforms may migrate earlier in LBCL/FL. (read more)
    • Strategic implications: Design frontline and low‑burden iNHL studies with PD biomarker gates; invest in combination rationales (EO2463+R²); strengthen referral networks for EBV‑driven T/NK transplant pathways. (read more)
Publications Related to Approved Drugs
Phase 2
axicabtagene ciloleucel
Indirect Treatment Comparisons of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in Third-Line or Later Relapsed or Refractory Follicular Lymphoma. Matching-adjusted indirect comparisons suggest that for patients with third-line or later relapsed or refractory follicular lymphoma, lisocabtagene maraleucel (liso-cel) demonstrates a higher complete response rate and a better safety profile compared to axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel). Liso-cel showed significantly reduced odds of severe cytokine release syndrome and neurological events compared to axi-cel, positioning it as a potentially preferred CAR T-cell therapy option in this setting. () .
PHASE1, PHASE2
epcoritamab-bysp
MRD-negativity by PBMCs and ctDNA confirms deep and durable responses following epcoritamab monotherapy in R/R FL. In the EPCORE NHL-1 study, the bispecific antibody epcoritamab induced rapid and deep molecular responses in patients with relapsed/refractory follicular lymphoma, with minimal residual disease (MRD) negativity achieved early in treatment. MRD-negativity by cycle 3, as measured by peripheral blood or ctDNA, was strongly correlated with prolonged progression-free survival, highlighting the value of MRD analysis to complement conventional imaging-based response assessments. () .
Phase 3
polatuzumab vedotin
Real-World Safety and Efficacy of Pola-R-CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients. This prospective observational study confirms the efficacy and safety of the Pola-R-CHP regimen in a real-world setting for previously untreated diffuse large B-cell lymphoma (DLBCL), including patients over 80 years old who were excluded from the pivotal POLARIX trial. The findings show high response rates and a safety profile consistent with the clinical trial, supporting its use in a broader patient population without new safety signals. () .
PHASE1, PHASE2
mosunetuzumab
Fixed Treatment Duration Mosunetuzumab in Patients With Relapsed or Refractory Follicular Lymphoma: Perspectives From US Advanced Practice Providers. Advanced Practice Providers (APPs) play a critical role in the successful administration of mosunetuzumab in the outpatient setting for relapsed or refractory follicular lymphoma. Their involvement in educating staff and patients, monitoring for adverse events like cytokine release syndrome, and managing toxicities is essential for ensuring patient safety and coordinating care within the multidisciplinary team. () .
Phase 2
tisagenlecleucel
Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL. The 5-year follow-up from the pivotal ELIANA trial demonstrates that tisagenlecleucel provides durable long-term survival and relapse-free survival for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. These findings reinforce the potential of this CAR T-cell therapy to be a definitive, curative treatment for a significant portion of this heavily pretreated patient population, with no new long-term safety concerns identified. () .
Phase 3
brentuximab vedotin
Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group (COG) AHOD1331 trial. In pediatric patients with Stage IV classic Hodgkin lymphoma, the addition of brentuximab vedotin to AVEPC chemotherapy improved progression-free survival across most patterns of extranodal disease, particularly in those with lung or bone involvement. However, this survival benefit was not observed in the subgroup of patients with bone marrow-only involvement, suggesting this specific patient cohort may require alternative therapeutic strategies. () .
PHASE1, PHASE2
sonrotoclax
Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor. Sonrotoclax, a next-generation BCL-2 inhibitor, showed rapid and durable responses in heavily pretreated patients with relapsed/refractory mantle cell lymphoma, including those with high-risk features like TP53 mutations. The monotherapy demonstrated a manageable safety profile, with low rates of tumor lysis syndrome, supporting its potential as a new oral therapeutic option for this difficult-to-treat population. () .
New Publications Related to Drugs in Clinical Trial Development
Phase 2
Infection Burden in Mismatched Unrelated Donor Hematopoietic Cell Transplantation: Results from the ACCESS Trial. This study quantifies the significant infection burden in adult patients undergoing mismatched unrelated donor HCT with post-transplant cyclophosphamide (PTCy), finding that acute GvHD is a major risk factor for infection. These results establish a critical benchmark for future trials aiming to mitigate infection risk in this high-risk patient population. ()
PHASE1, PHASE2
Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. In the FELIX study, the CD19-directed CAR T-cell therapy obecabtagene autoleucel (obe-cel) demonstrated significantly higher remission rates and longer overall survival compared to standard-of-care non-CAR T-cell therapies in adults with relapsed/refractory B-ALL. This positions obe-cel as a superior therapeutic option that could address a critical unmet need in this patient population. ()
PHASE1, PHASE2
CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study. This analysis from the FELIX study establishes that droplet digital PCR (ddPCR) is a more sensitive method than flow cytometry for detecting obe-cel persistence in R/R B-ALL patients. Importantly, CAR T-cell persistence detected by ddPCR at month 3 correlates with longer event-free survival, highlighting its potential as a key biomarker for clinical decision-making. ()
Phase 2
Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study. In newly diagnosed primary mediastinal large B-cell lymphoma (PMBL), monitoring for circulating tumor DNA (ctDNA) after four cycles of frontline therapy is a powerful predictor of progression-free survival, showing a higher positive predictive value than PET scans. This study supports the integration of ctDNA monitoring as a valuable tool to complement PET response criteria and guide future risk-adapted strategies in PMBL. ()
PHASE1, PHASE2
Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial. The combination of the CD19-4-1BBL co-stimulatory molecule, englumafusp alfa, with the T-cell engaging bispecific antibody glofitamab demonstrates encouraging efficacy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. This novel combination achieved high response rates, particularly in CAR-T naive patients, with a safety profile consistent with glofitamab monotherapy. ()
Phase 2
Frequency, kinetics, and clinical significance of HHV-6 DNAemia after PTCy-based hematopoietic cell transplant. High-level HHV-6 DNAemia is a frequent event in patients receiving post-transplant cyclophosphamide (PTCy)-based HCT, occurring at a median of 27 days post-transplant. While rarely causing classic encephalitis, it is associated with increased rates of unexplained fever, rash, and GVHD, suggesting it may serve as an important marker for increased immune-related complications. ()
Phase 2
Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL. With a median follow-up of over 41 months, a single infusion of lisocabtagene maraleucel (liso-cel) provides durable efficacy and high survival rates in patients with third-line or later follicular lymphoma, including high-risk subgroups. The long-term safety profile remains favorable, with decreasing rates of cytopenias and infections over time, reinforcing its role as a key therapeutic option. ()
Phase 2
Indirect Treatment Comparisons of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in Third-Line or Later Relapsed or Refractory Follicular Lymphoma. Through matching-adjusted indirect comparisons, lisocabtagene maraleucel (liso-cel) demonstrated a significantly higher complete response rate compared to both axicabtagene ciloleucel and tisagenlecleucel in 3L+ R/R follicular lymphoma. Liso-cel also showed a better safety profile than axi-cel, suggesting it may be a preferred CAR T-cell therapy option in this setting. ()
PHASE1, PHASE2
A distinct CAR-T cell phenotype mediates therapeutic response at limited doses. This study identifies that the efficacy of low-dose anti-CD19 CAR-T cell therapy in B-cell lymphomas is driven by an enrichment of functional effector and effector memory-like CAR-T cells. The absolute number of these cells serves as a robust biomarker for therapeutic response, suggesting that product composition, not just dose, is a critical determinant of clinical success. ()
Phase 1
Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm. The triplet combination of tagraxofusp, azacitidine, and venetoclax demonstrates high rates of complete remission in both newly diagnosed (88%) and relapsed/refractory (64%) blastic plasmacytoid dendritic cell neoplasm (BPDCN). This regimen shows a manageable safety profile and facilitates a high proportion of patients proceeding to allogeneic stem cell transplant, supporting its use as a new therapeutic standard. ()
PHASE1, PHASE2
Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation. This modeling analysis confirms that the approved step-up dosing regimens for epcoritamab, combined with prophylaxis including dexamethasone, are effective at mitigating the risk of Grade ≥2 cytokine release syndrome (CRS) in patients with relapsed/refractory large B-cell and follicular lymphomas. The study also found that prior CAR T-cell therapy was associated with a significant reduction in the risk of developing CRS. ()
PHASE1, PHASE2
Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004. The combination of lisocabtagene maraleucel (liso-cel) with concurrent ibrutinib yields high response rates and durable remissions in heavily pretreated patients with relapsed/refractory CLL/SLL, including those with prior BTK inhibitor and venetoclax failure. With a median follow-up of nearly 25 months, the therapy demonstrated a complete response rate of 45% and a manageable safety profile, offering a promising new option for this high-risk population. ()
Phase 1
Rocbrutinib, a Highly Selective Fourth-Generation Covalent and Noncovalent BTK Inhibitor, in R/R Non-GCB DLBCL: Efficacy and Safety from a Phase I Study. The fourth-generation BTK inhibitor rocbrutinib shows promising efficacy in heavily pretreated patients with relapsed/refractory non-GCB diffuse large B-cell lymphoma, achieving an overall response rate of 57.8% and a complete response rate of 33.3%. The agent demonstrated a favorable safety profile, notably with no reported cases of atrial fibrillation, supporting a recommended Phase 2 dose of 200 mg once daily. ()
PHASE1, PHASE2
Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma. An adjusted comparative analysis shows that the combination of epcoritamab plus lenalidomide and rituximab (R²) significantly improves response rates, duration of response, progression-free survival, and overall survival compared to standard-of-care chemoimmunotherapy or R² alone in patients with relapsed/refractory follicular lymphoma. These findings support this triplet regimen as a highly effective, chemotherapy-free treatment option for this patient population. ()
Phase 3
Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial. The addition of the non-covalent BTK inhibitor pirtobrutinib to a fixed-duration venetoclax-rituximab regimen resulted in a significant improvement in progression-free survival for patients with previously treated CLL/SLL, including those with prior exposure to covalent BTK inhibitors. This Phase 3 trial establishes the pirtobrutinib-containing triplet as a potential new standard of care in the relapsed/refractory setting. ()
Phase 3
Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826). In the SWOG S1826 trial for advanced-stage classic Hodgkin lymphoma, nivolumab-AVD (N-AVD) significantly improved progression-free survival compared to brentuximab vedotin-AVD, abrogating the historically poor prognosis associated with EBV-positive status and non-nodular sclerosis histology. These results strongly support N-AVD as the frontline standard of care, particularly for these high-risk biological subgroups. ()
Phase 1
Engineering allogeneic type 1 regulatory T cells: a scalable, off-the-shelf platform for restoring immune tolerance. This research details the development of TRX103, an engineered, allogeneic "off-the-shelf" Type 1 regulatory T (Tr1) cell therapy designed to restore immune tolerance. Preclinical data show TRX103 effectively suppresses effector T-cell proliferation and prevents disease in a xenogeneic GvHD model, supporting its ongoing clinical evaluation for GvHD prevention and treatment-refractory Crohn's disease. ()
Phase 2
Blinatumomab consolidation for high-risk Ph- B-cell acute lymphoblastic leukemia: the GRAALL-2014/B-QUEST study. Integrating blinatumomab into consolidation and maintenance therapy for adults with high-risk Philadelphia chromosome-negative B-ALL significantly improved measurable residual disease (MRD) clearance, reduced relapse rates, and prolonged survival compared to historical controls. These findings support the frontline integration of blinatumomab for this patient population and prompt a re-evaluation of transplantation strategies. ()
Early Phase 1
Ultralow-Dose Interleukin 10-Expressing Chimeric Antigen Receptor T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Nonrandomized Clinical Trial. An ultralow-dose of IL-10-expressing CD19 CAR T-cells (META 10-19) demonstrated remarkable antitumor activity in patients with relapsed/refractory DLBCL, achieving a complete remission rate of 84.6% with a manageable safety profile. This study suggests that this novel CAR T-cell construct is highly potent even at doses significantly lower than conventional CAR T-cell therapies. ()
Phase 2
Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma. The oral PI3K-δ/γ inhibitor duvelisib demonstrated significant clinical activity in relapsed/refractory peripheral T-cell lymphoma (PTCL), with an overall response rate of 48% and a complete response rate of 33.3%. Efficacy was particularly pronounced in the angioimmunoblastic T-cell lymphoma (AITL) subgroup, providing a strong rationale for its further development in PTCL. ()
Phase 3
Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy. In the TRANSFORM study for second-line large B-cell lymphoma, lisocabtagene maraleucel (liso-cel) achieved deeper and more durable molecular clearance, as measured by circulating tumor DNA (ctDNA), compared to standard of care. ctDNA-based minimal residual disease (MRD) status provided prognostic value beyond PET scans, supporting its role as a complementary biomarker for response assessment and relapse prediction. ()
Phase 2
Updated Integrated Safety Analysis of Ritlecitinib up to ~ 5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program. In a long-term safety analysis from the ALLEGRO program, the JAK3/TEC family kinase inhibitor ritlecitinib was generally well-tolerated for up to approximately 5 years in patients with alopecia areata. The overall safety profile, including rates of serious adverse events and malignancies, remained consistent with previously reported data, supporting its long-term use. ()
Phase 3
CD20 expression dynamics in adult B-cell acute lymphoblastic leukemia and impact on anti-CD20 treatment. This study reveals that CD20 expression in adult B-ALL is dynamic, often increasing from baseline bone marrow assessment to post-prephase blood measurements. Utilizing the highest recorded CD20 expression value better predicts early measurable residual disease (MRD) responses to rituximab-containing regimens, suggesting that reassessing CD20 in blood after the prephase can identify additional patients who may benefit from anti-CD20 therapy. ()
Phase 2
Low-dose chidamide maintenance therapy following allogeneic hematopoietic cell transplantation in T-cell acute lymphoblastic leukemia or lymphomas: a phase II, open-label, multicenter, single-arm trial. Low-dose maintenance therapy with the histone deacetylase inhibitor chidamide following allogeneic HCT for T-ALL and T-cell lymphomas resulted in a promising 2-year relapse-free survival of 83.7%. The treatment was manageable with predominantly low-grade adverse events, suggesting it could be a potential prophylactic strategy to reduce post-transplant relapse in this high-risk population. ()
PHASE1, PHASE2
A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma. A dose-dense strategy involving a second infusion of JCAR014 CAR T-cells at day 14, without repeat lymphodepletion, was found to be safe and led to durable long-term responses in patients with R/R B-cell non-Hodgkin lymphoma. This approach resulted in CAR T-cell re-expansion after the second dose and compared favorably to historical outcomes from single-infusion cohorts, suggesting a potential new strategy to improve efficacy. ()
Phase 2
Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm. In a comparative effectiveness study, the T-cell engaging bispecific antibody glofitamab, administered with a short ramp-up, significantly improved overall survival and nearly halved the risk of death compared to contemporaneous non-bispecific salvage therapies for patients with DLBCL who failed anti-CD19 CAR T-cell therapy. These robust findings support the use of glofitamab as a preferred treatment option in this challenging post-CAR T setting. ()
Phase 3
Toxicity from asparaginase during acute lymphoblastic leukemia induction: a report from the Children's Oncology Group. In a large analysis of pediatric and young adult ALL patients, older age (≥10 years) and the combination of obesity with high body surface area were identified as significant risk factors for developing asparaginase-associated toxicities during induction therapy. These findings highlight the need for preventive strategies in these specific patient subgroups to mitigate treatment-related complications. ()
Phase 4
CD20 expression dynamics in adult B-cell acute lymphoblastic leukemia and impact on anti-CD20 treatment. This study reveals that CD20 expression in adult B-ALL is dynamic, often increasing from baseline bone marrow assessment to post-prephase blood measurements. Utilizing the highest recorded CD20 expression value better predicts early measurable residual disease (MRD) responses to rituximab-containing regimens, suggesting that reassessing CD20 in blood after the prephase can identify additional patients who may benefit from anti-CD20 therapy. ()
Phase 3
Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX. A pooled analysis of the ALEX and J-ALEX trials identified high tumor burden as a negative prognostic factor for both progression-free and overall survival in ALK-positive NSCLC. The survival benefit of alectinib over crizotinib was more pronounced in patients with low tumor burden, suggesting that treatment intensification strategies may be needed for high-burden patients. ()
Phase 2
Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial. This molecular analysis of the V-RBAC trial in elderly mantle cell lymphoma patients identified that beyond TP53 mutations, CDKN2A loss, CD36 mutations, and single-hit ATM abnormalities are independently associated with progression-free survival. These findings were integrated into a novel 4-factor molecular prognostic model that better stratifies patients, highlighting the importance of comprehensive molecular profiling for precise risk assessment. ()
Phase 3
First-line ibrutinib plus venetoclax for non-blastoid mantle cell lymphoma in patients ≥65 years or with TP53 mutations. The combination of ibrutinib and venetoclax as a first-line, fixed-duration therapy demonstrates high complete response rates (69%) and durable remissions in older (≥65 years) or TP53-mutated patients with non-blastoid mantle cell lymphoma. With a median progression-free survival of 40.2 months, this chemotherapy-free regimen presents a promising new option for this high-risk population. ()
Clinical Trials
Clinical Trials Summary
Number of Clinical Trials in lymphoma updated from 2026-07-01 to 2026-07-31:
Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Total
Enrolling by Invitation-------
Not Yet Recruiting1041723-36
Recruiting332047181110
Available-------
Approved for Marketing-------
Active, Not Recruiting23944316-95
Completed-------
Total66331086271241
Phase 1 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
: MB-CART19.1 NCT03853616 ACTIVE_NOT_RECRUITING A Phase I Safety, Dose Finding and Feasibility Trial of MB-CART19.1 in Patients With Relapsed or Refractory CD19 Positive B Cell Malignancies 2026-09
Temozolomide, Telaglenastat Hydrochloride NCT03528642 ACTIVE_NOT_RECRUITING A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma 2026-09-11
bleximenib, 14C-bleximenib NCT07295951 RECRUITING An Open-Label Study to Investigate the Absorption, Metabolism, And Excretion (AME) Of 14C-Bleximenib (JNJ-75276617) in Participants With Acute Leukemia 2026-09-29
Phase 2 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
: Ublituximab, Umbralisib, Acalabrutinib NCT04783415 ACTIVE_NOT_RECRUITING A Phase II Study of BTK Inhibitor Acalabrutinib and PI3Kδ Inhibitor Umbralisib in Combination With Ublituximab (AU2) in Patients With Previously Untreated Mantle Cell Lymphoma (MCL) 2026-07-21
Ibrutinib, Palbociclib NCT03478514 ACTIVE_NOT_RECRUITING A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma 2026-08-30
Inotuzumab Ozogamicin (IO) NCT03610438 ACTIVE_NOT_RECRUITING A Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin (IO) in Adult Patients With B-Cell Acute Lymphoblastic Leukemia With Positive Minimal Residual Disease Before Any Hematopoietic Stem Cell Transplantation 2026-10
Ensartinib NCT03213652 ACTIVE_NOT_RECRUITING NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations 2026-10-03
Phase 3 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Asparaginase, Dexamethasone, Vincristine, Mercaptopurine, Mitoxantrone Hydrochloride, Methotrexate, Vincristine Sulfate, Mitoxantrone, Therapeutic Hydrocortisone, Thioguanine, Etoposide, Leucovorin Calcium, Cytarabine, Cyclophosphamide, Pegaspargase, : Blinatumomab NCT02101853 ACTIVE_NOT_RECRUITING Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) 2026-09-16
Daunorubicin, Doxorubicin, Dexamethasone, Mercaptopurine, Doxorubicin Hydrochloride, Vincristine, Bortezomib, Daunorubicin Hydrochloride, Methotrexate, Vincristine Sulfate, Thioguanine, Etoposide, Leucovorin Calcium, Cytarabine, Cyclophosphamide, Hydrocortisone Sodium Succinate, Pegaspargase, Ifosfamide NCT02112916 ACTIVE_NOT_RECRUITING A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) 2026-09-16
Methylprednisolone, Doxorubicin Hydrochloride, Vincristine Sulfate, Prednisone, Etoposide, : Bleomycin Sulfate, Brentuximab Vedotin, Cyclophosphamide NCT02166463 ACTIVE_NOT_RECRUITING A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults 2026-10-03
Phase 4 Clinical Trials within 3 Months of Primary Completion Date:
No phase 4 trials completing within the next three months.
NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.